Waqas Jehangir, MD
Hematology & Oncology · Sioux Falls, SDNPI 1659752541
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $21,191 of the $22,876 with a category attached, or 92.6%. 22 manufacturers reported payments, led by Servier Pharmaceuticals LLC at 25.3% of the total. Reporting peaked in 2022 at $8,171 and has fallen 58.4% since, to $3,402 in 2025.
Across 48 payments — averaging $476.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Servier Pharmaceuticals LLC$6K
- E.r. Squibb & Sons, L.L.C.$4K
- Beigene USA, Inc.$3K
- Janssen Scientific Affairs, LLC$3K
- Daiichi Sankyo Inc.$2K
- Morphosys, US Inc.$1K
- plus $4K from 16 others
Across 88 payments — averaging $7669.71 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$359K
- Deciphera Pharmaceuticals Inc.$141K
- ADC Therapeutics America, Inc.$76K
- Gilead$64K
- Janssen Research & Development, LLC$18K
- Incyte Corporation$10K
- plus $7K from 2 others
What the payments were for
- Consulting fees$21,19193%
- Travel & lodging$8714%
- Food & beverage$4802%
- Education$3341%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Servier Pharmaceuticals LLC | 8 | $5,799 |
| E.r. Squibb & Sons, L.L.C. | 4 | $3,830 |
| Beigene USA, Inc. | 2 | $2,950 |
| Janssen Scientific Affairs, LLC | 7 | $2,906 |
| Daiichi Sankyo Inc. | 2 | $2,060 |
| Morphosys, US Inc. | 1 | $1,440 |
| AstraZeneca(2 entities) | 3 | $1,225 |
| GSK | 2 | $655 |
| Vertex | 1 | $400 |
| Cardinal Health 110 LLC | 2 | $400 |
| Pfizer | 2 | $325 |
| Sobi, Inc | 1 | $200 |
| Amgen | 2 | $165 |
| Novartis | 2 | $142 |
| Geron Corporation | 1 | $106 |
| Astellas Pharma US Inc | 1 | $95 |
| Legend Biotech USA Inc. | 2 | $57 |
| Bristol Myers Squibb | 1 | $44 |
| Mallinckrodt Hospital Products Inc. | 1 | $25 |
| Rigel Pharmaceuticals, Inc. | 1 | $19 |
| Genentech USA, Inc. | 1 | $18 |
| Biolinerx USA, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$22,876 in reported general payments places this provider in the 85th percentile of 28 hematology & oncology providers in South Dakota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RevlimidLenalidomide | 56 | $925,877 |
| CalquenceAcalabrutinib Maleate | 39 | $581,513 |
| SprycelDasatinib | 16 | $291,108 |
| PomalystPomalidomide | 15 | $239,526 |
| BrukinsaZanubrutinib | 17 | $234,860 |
| ImbruvicaIbrutinib | 14 | $227,268 |
| VenclextaVenetoclax | 22 | $202,596 |
| TasignaNilotinib Hcl | 14 | $181,251 |
| JakafiRuxolitinib Phosphate | 11 | $172,573 |
| InqoviDecitabine/Cedazuridine | 17 | $79,300 |
| EliquisApixaban | 49 | $52,006 |
| XareltoRivaroxaban | 24 | $28,343 |
| BexseroMeningococcal B Vaccine,4-Comp | 14 | $2,913 |
| Dexamethasone | 107 | $2,475 |
| ShingrixVaricella-Zoster Ge/As01b/Pf | 12 | $2,209 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bristol Myers SquibbRevlimid | $44 | $925,87756 claims |
| AstraZenecaCalquence | $1,225 | $581,51339 claims |
| E.r. Squibb & Sons, L.L.C.Sprycel, Pomalyst | $3,830 | $530,63331 claims |
| Beigene USA, Inc.Brukinsa | $2,950 | $234,86017 claims |
| NovartisTasigna | $142 | $181,25114 claims |
| PfizerEliquis | $325 | $52,00649 claims |
| GSKBexsero, Shingrix, Twinrix, Hiberix | $655 | $7,34361 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 28 hematology & oncology providers in South Dakota.
Other hematology & oncology in Sioux Falls
- Kelly McCaulSioux Falls$1.2M
- Roberto Ferro ValdesSioux Falls$142K
- Steven PowellSioux Falls$13K
- Benjamin SolomonSioux Falls$5K
- Miroslaw MazurczakSioux Falls$2K
- Mark HuberSioux Falls$1K
- Ryan VacaSioux Falls$1K
- Michael McHaleSioux Falls$811
- Heidi McKeanSioux Falls$552
- Allison WatsonSioux Falls$254
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.